Stoke Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
STOK$27.21-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of cash flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net income (loss) | $112,879 | $(26,374) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: | ||
| Depreciation | 477 | 563 |
| Amortization and accretion of marketable securities | (494) | (24) |
| Stock-based compensation | 6,753 | 5,410 |
| Reduction in the carrying amount of right of use assets | 599 | 550 |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other current assets | (2,555) | (349) |
| Accounts payable, accrued liabilities and lease liabilities | 4,741 | (1,919) |
| Deferred revenue | 9,427 | (2,423) |
| Net cash provided by (used in) operating activities | 131,827 | (24,566) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (19,016) | — |
| Purchases of property and equipment | (152) | (12) |
| Sales of marketable securities | 32,800 | 10,000 |
| Net cash provided by investing activities | 13,632 | 9,988 |
| Cash flows from financing activities: | ||
| Proceeds from Employee Stock Purchase Plan | 370 | 168 |
| Proceeds from issuance of common stock upon exercise of stock options | 1,004 | 250 |
| Proceeds from issuance of common stock in controlled equity offering sales agreements | — | 1,299 |
| Net cash provided by financing activities | 1,374 | 1,717 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 146,833 | (12,861) |
| Cash, cash equivalents and restricted cash—beginning of period | 128,780 | 192,011 |
| Cash, cash equivalents and restricted cash—end of period | $275,613 | $179,150 |
| Supplemental Disclosure of Non-Cash Investing and Financing Activities: | ||
| Property and equipment included in accrued expense and accounts payable | $27 | $6 |
| Deferred offering costs not yet paid | $— | $402 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.